Gilead Sciences (GILD) said Friday that a phase 3 trial comparing its drug Trodelvy with chemotherapy as a first-line treatment post-endocrine therapy in HR+/HER2-negative metastatic breast cancer did not meet the primary endpoint of progression-free survival.

The study, which enrolled 654 patients in nearly 30 countries, will continue to assess Trodelvy to see if it meets the secondary endpoint of overall survival, the company said.

The safety profile of the drug was consistent with previous Trodelvy breast cancer studies, the company said.

Trodelvy is currently approved in several countries for second-line or later metastatic triple-negative breast cancer patients as well as for patients with pre-treated HR+/HER2-negative metastatic breast cancer, Gilead said.

Shares of the company were up 1.3% in recent premarket activity Friday.